Results 1 to 10 of about 24,495 (214)

Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect

OncoImmunology, 2021
Background Immunosuppressive cell-based therapy is a recent strategy for controlling Graft-versus-Host Disease (GvHD). Such cells ought to maintain their suppressive function in inflammatory conditions and in the presence of immunosuppressive agents ...
Nona Janikashvili, Claire Gérard, Marine Thébault, Andrea Brazdova, Clovis Boibessot, Claudie Cladière, Marion Ciudad, Hélène Greigert, Séthi Ouandji, Thibault Ghesquière, Maxime Samson, Sylvain Audia, Philippe Saas, Bernard Bonnotte   +13 more
doaj   +1 more source

Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial

BMJ Oncology, 2023
Objective Vaccinated patients with cancer in follow-up studies showed a high seropositivity rate but impaired antibody titres and T cell responses following mRNA vaccine against COVID-19.
Laura Mansi, Olivier Adotevi, Marie Kroemer, Laurie Spehner, Adeline Bouard, Marine Jary, Romain Loyon, Christophe Borg, Dewi Vernerey, Syrine Abdeljaoued, Myriam Ben Khelil, Quentin Lepiller, Emeline Orillard, Antoine Falcoz, Hamadi Almotlak, Stefano Kim, Elsa Curtit, Guillaume Meynard, Charlee Nardin, Kamal Asgarov, Ugo Chartral, Virginie Mougey, Morgane Lopez   +22 more
doaj   +1 more source

Validation of a method evaluating T cell metabolic potential in compliance with ICH Q2 (R1)

Journal of Translational Medicine, 2021
Background Metabolic cell features are able to give reliable information on cell functional state. Thus, metabolic potential assessment of T cells in malignancy setting represents a promising area, especially in adoptive cell therapy procedures.
Patricia Mercier-Letondal, Chrystel Marton, Yann Godet, Jeanne Galaine   +3 more
doaj   +1 more source

Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells

Frontiers in Immunology, 2022
Cancers are consequences of cellular dysfunction leading to an aberrant cellular multiplication and proliferation, subsequently yielding metastasis formation.
Audrey Wetzel, Audrey Wetzel, Francis Bonnefoy, Francis Bonnefoy, Cécile Chagué, Mathieu Vetter, Mélanie Couturier, Blandine Baffert, Olivier Adotévi, Olivier Adotévi, Philippe Saas, Sylvain Perruche, Sylvain Perruche   +12 more
doaj   +1 more source

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity

eJHaem, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these
Margaux Poussard, Laure Philippe, Maxime Fredon, Elodie Bôle‐Richard, Sabeha Biichle, Florian Renosi, Sophie Perrin, Marie Kroemer, Samuel Limat, Francis Bonnefoy, Etienne Daguindau, Eric Deconinck, Bérengère Gruson, Philippe Saas, Olivier Adotévi, Francine Garnache‐Ottou, Fanny Angelot‐Delettre   +16 more
doaj   +1 more source

Resolution therapy: Harnessing efferocytic macrophages to trigger the resolution of inflammation

Frontiers in Immunology, 2022
Several chronic inflammatory diseases are associated with non-resolving inflammation. Conventional anti-inflammatory drugs fail to completely cure these diseases.
Philippe Saas, Mathieu Vetter, Melissa Maraux, Francis Bonnefoy, Francis Bonnefoy, Sylvain Perruche, Sylvain Perruche   +6 more
doaj   +1 more source

Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases

Journal for ImmunoTherapy of Cancer, 2020
Background The positive role of CD8+ tumor-infiltrating lymphocytes (TIL) in patients with colorectal cancer (CRC) has been well described but the prognostic value of CD4 T cell subsets remained to be investigated.
Olivier Adotevi, Marie Kroemer, Celia Turco, Laurie Spehner, Julien Viot, Idir Idirène, Adeline Bouard, Elodie Renaude, Marina Deschamps, Yann Godet, Samuel Limat, Bruno Heyd, Marine Jary, Romain Loyon, Christophe Borg   +14 more
doaj   +1 more source

The ATG8 Family Proteins GABARAP and GABARAPL1 Target Antigen to Dendritic Cells to Prime CD4⁺ and CD8⁺ T Cells

Cells, 2022
Vaccine therapy is a promising method of research to promote T cell immune response and to develop novel antitumor immunotherapy protocols. Accumulating evidence has shown that autophagy is involved in antigen processing and presentation to T cells.
Leïla Fonderflick, Timothée Baudu, Olivier Adotévi, Michaël Guittaut, Pascale Adami, Régis Delage-Mourroux   +5 more
doaj   +1 more source

Immunothérapie du cancer : espoirs et réalités [PDF]

, 2006
Au cours des deux dernières décennies, l’immunologie des tumeurs a connu un réel bouleversement et un foisonnement de découvertes fondamentales qui se sont traduites en applications cliniques.
Benlalam, Houssem, Chouaib, Salem, Hage, Faten El, Mami-Chouaib, Fathia   +3 more
core   +1 more source

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma

OncoImmunology, 2018
Tumor cells, which undergo Epithelial-mesenchymal transition (EMT) acquire increased capacities of proliferation, invasion and have the ability to generate metastases by escaping the immune system during their systemic migration.
A. Asgarova, K. Asgarov, Y. Godet, P. Peixoto, A. Nadaradjane, M. Boyer-Guittaut, J. Galaine, D. Guenat, V. Mougey, J. Perrard, J. R. Pallandre, A. Bouard, J. Balland, C. Tirole, O. Adotevi, E. Hendrick, M. Herfs, P. F. Cartron, C. Borg, E. Hervouet   +19 more
doaj   +1 more source